The Effect of miR-361-3p Targeting TRAF6 on Apoptosis of Multiple Myeloma Cells
Zhen Fan1, Zhiwei Wu1, Bo Yang1
1Department of Hematology, The First People's Hospital of Jingmen, No. 67 Xiangshan Avenue, Jingmen, Hubei Province 448000, P.R. China.
Abstract:
microRNA-361-3p (miR-361-3p) is involved in the carcinogenesis of oral cancer and pancreatic catheter adenocarcinoma, and has anti-carcinogenic effects on non-small cell lung cancer (NSCLC). However, its effect on multiple myeloma (MM) is less reported. Here, we found that upregulating the expression of miR-361-3p inhibited MM cell viability and promoted MM apoptosis. We measured expressions of tumor necrosis factor receptor-associated factor 6 (TRAF6) and miR-361-3p in MM cells and detected the viability, colony formation rate, and apoptosis of MM cells. In addition, we measured expressions of apoptosis-related genes Bcl-2, Bax, and Cleaved caspase-3 (C caspase-3). The binding site between miR-361-3p and TRAF6 was predicted by TargetScan. Our results showed that miR-361-3p was low expressed in the plasma of MM patients and cell lines, while its overexpression inhibited viability and colony formation of MM cells and increased the cell apoptosis. Furthermore, TRAF6, which was predicted to be a target gene of miR-361-3p, was highexpressed in the plasma of patients and cell lines with MM. Rescue experiments demonstrated that the effect of TRAF6 on MM cells was opposite to that of miR-361-3p. Upregulation of miR-361-3p induced apoptosis and inhibited the proliferation of MM cells through targeting TRAF6, suggesting that miR-361-3p might be a potential target for MM therapy.
Insights
microRNA-361-3p (miR-361-3p) is downregulated in multiple myeloma (MM). Upregulating miR-361-3p inhibits MM cell growth and promotes apoptosis by targeting TRAF6, suggesting its therapeutic potential.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- microRNA-361-3p (miR-361-3p) has known roles in various cancers, but its function in multiple myeloma (MM) is under-investigated.
- Understanding miR-361-3p's role in MM is crucial for identifying novel therapeutic targets.
Purpose of the Study:
- To investigate the expression and function of miR-361-3p in multiple myeloma (MM).
- To explore the potential of miR-361-3p as a therapeutic agent for MM.
Main Methods:
- Quantitative real-time PCR to measure miR-361-3p and TRAF6 expression in MM patients and cell lines.
- Cell viability assays (MTT), colony formation assays, and apoptosis assays (flow cytometry) to assess MM cell behavior.
- Bioinformatic prediction (TargetScan) and rescue experiments to elucidate the miR-361-3p/TRAF6 interaction.
Main Results:
- miR-361-3p was significantly downregulated in MM patient plasma and cell lines.
- Overexpression of miR-361-3p inhibited MM cell viability and colony formation while promoting apoptosis.
- TRAF6, a predicted target of miR-361-3p, was upregulated in MM and its effects were opposite to miR-361-3p.
- miR-361-3p suppressed MM progression by targeting TRAF6, impacting apoptosis-related genes like Bcl-2, Bax, and Cleaved caspase-3.
Conclusions:
- miR-361-3p acts as a tumor suppressor in multiple myeloma.
- Targeting miR-361-3p represents a promising therapeutic strategy for multiple myeloma treatment.
More Related Videos
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
12:28Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
